This week in transparency news: September 8-14, 2018

by Staff writer,
Posted on 9/14/2018

Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:

Half of EU’s trial results go unreported, EU Trials Tracker launched Quartz

Approximately 49 percent of clinical trials in the EU have failed to report their results, according to a new study. Reasons cited include time, lack of punishment, and a focus on publishing in journals instead. Oxford’s Evidence Based Medicine DataLab launched the new EU Trials Tracker on the heels of reporting these results in a recent paper with The BMJ. The EU Trials Tracker is described as “a searchable website that seeks to hold trial investigators accountable for properly reporting results.”

Read the full article here.

Report on first 1000 trials in Pan African Clinical Trial Registry (PACTR) published Cochrane

A new paper presented at the Cochrane Colloquium analyzed the first 1000 African-controlled clinical trials registered in PACTR. It was found that registration on PACTR has grown since 2009, with over half the studies registered from Egypt. Approximately 25% of registered trials covered infectious and parasitic diseases, reflecting local burdens. Maternal-child health was prevalent as well. Studies were primarily single-center trials conducted in adults, with the majority of funding at the university level. Many retrospective trials were registered, but there is a growing need to raise awareness for registering prospective clinical trials.

Read the paper here.

Updated announced for ClinicalTrials.govNIH

The NIH announced three updates to the Protocol Registration and Results System (PRS) for ClinicalTrials.gov. These updates include study document (PDF/A) upload changes, new results validation messages intended to reduce major issues, and results edit participant flow.

Understand each of the changes here.

Share: